According to the Complaint, Envision Healthcare Corporation ("Envision" or the "Company"), through its subsidiaries, provides various healthcare services in the United States. Envision operates through two segments, Physician Services and Ambulatory Services.

According to the Complaint, Glencore PLC (“Glencore” or the “Company”) engages in the production, refinement, processing, storage, transport and marketing of metals and minerals, energy products, and agricultural products worldwide. Glencore is incorporated in Jersey, United Kingdom, with headquarters in Baar, Switzerland. Glencore operates mines in the Democratic Republic of Congo (“DRC”).

According to the Complaint, Gogo Inc. ("Gogo" or the "Company"), through its subsidiaries, provides inflight broadband connectivity and wireless entertainment services to the aviation industry in the United States and
internationally.

According to the Complaint, the Company describes itself as "developing and commercializing a robotic device, the ARTAS System that assists physicians in performing many of the repetitive tasks that are a part of a follicular unit extraction surgery, a type of hair restoration procedure."

According to the Complaint, TAL Education Group ("TAL") provides educational services, and offers comprehensive tutoring services to students covering core academic subjects such as mathematics, English, Chinese, physics,
chemistry. The Company mainly serves students in China.

According to the Complaint, PG&E was incorporated in California in 1995 as a holding company whose primary
operating subsidiary is Pacific Gas and Electric, a public utility operating in northern and central California. The Company generates revenues mainly through the sale and delivery of electricity and natural gas to customers.

According to the Complaint, Ormat Technologies Inc. ("Ormat") engages in the geothermal and recovered energy power business worldwide.

Plaintiff's law firm issued a press release on June 8, 2018, announcing the lawsuit on behalf of purchasers of REV Group, Inc. (NYSE:REVG) securities pursuant and/or traceable to REV Group's initial public offering ("IPO") on or about January 27, 2017. The Complaint alleges that Defendants made false and/or misleading statements and/or failed to disclose that: (1) REV Group was unable to use its "strong visibility into future net sales" to "effectively plan" and manage its backlog of vehicles; (2) REV Group facilities were not operating efficiently or at a low cost to satisfy customer demand; and (3) as a result, defendants' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

According to the Complaint, Aegean Marine Petroleum Network Inc. ("Aegean") is a marine fuel logistics company that markets and physically supplies refined marine fuel and lubricants to vessels in port, at sea, and on rivers. Aegean procures marine fuel from refineries, major oil producers, and other sources along with reselling and delivering these fuels from its bunkering vessels to end users.

According to the Complaint, Aegean Marine Petroleum Network Inc. ("Aegean") is a marine fuel logistics company that markets and physically supplies refined marine fuel and lubricants to vessels in port, at sea, and on rivers. Aegean procures marine fuel from refineries, major oil producers, and other sources along with reselling and delivering these fuels from its bunkering vessels to end users.

According to the law firm press release, Recro is a specialty pharmaceutical company that develops non-opioid therapeutics for the treatment of pain in the post-operative setting. Recro offers its products to the medical industry. The Company's lead product is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor ("IV meloxicam") to be used for the management of moderate to severe pain.

Fluor Corporation ("Fluor") is a holding company providing through various entities engineering, procurement, construction, fabrication and modularization, commissioning and maintenance and management services for clients (including the U.S. federal government) in industries such as oil and gas, chemicals and petrochemicals, mining and metals, transportation, power, life sciences and advanced manufacturing.

Oclaro, Inc. ("Oclaro") designs, manufactures, and markets optical components, modules, and subsystems for the long-haul, metro, and data center markets worldwide.

According to the Complaint, Symantec Corporation ("Symantec" or the "Company") provides cybersecurity solutions worldwide.

According to the law firm press release, Molina Healthcare, Inc. ("Molina") is a managed care company, focused on 4.5 million members eligible for Medicaid, Medicare, and other government-sponsored healthcare programs. Molina's health plans are operated by various wholly-owned subsidiaries, each of which is licensed as a health maintenance organization (HMO).

According to the Complaint, Allegiant Travel Company focuses on the provision of travel services and products to residents of under-served cities in the United States. The Company offers scheduled air transportation on limited frequency nonstop flights between under-served cities and leisure destinations.

According to the law firm press release, Longfin is a finance and technology company that provides trade and physical commodities solutions for finance businesses and trading platforms. Longfin recently began using blockchain technology to enable global trade finance solutions.

According to the law firm press release, Celgene is a biotechnology company that specializes in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its most successful drug is Revlimid, a drug for the treatment of multiple myeloma (a type of plasma cell cancer). However, Revlimid will lose its patent exclusivity in the coming years, at which point cheaper generics will be able to enter the market. As a result, it was important that the Company develop and successfully commercialize new drugs to diversify and ultimately replace its reliance on revenues from Revlimid sales, with the three most promising replacements being GED-0301, a late-stage developmental treatment for Crohn's disease, Otezla, a commercial-stage treatment for psoriasis, and Ozanimod, a developmental treatment for relapsing multiple sclerosis and ulcerative colitis.

Patterson Companies, Inc. ("Patterson") is one of the nation's only full-service distributors of dental products. The Company distributes its products mainly through two subsidiaries—Patterson Dental and Patterson Animal Health.

Before the Merger, EarthLink was a network services company.